- Home
- SNY
SNY
Sanofi ADS
as of 11-12-2026 1:05pm EST
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
| Founded: | 1994 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 95.7B | IPO Year: | 2001 |
| Target Price: | $54.92 | AVG Volume (30 days): | 4.7M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $39.07 - $52.67 | Next Earning Date: | 10-30-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4.7% | Revenue Growth (next year): | 5.35% |
| P/E Ratio: | 6.14 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +6.29% |
Compare SNY vs Leading Stocks
See how SNY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.